Analysis of Short-term (Operating) Activity Ratios
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
IQVIA Holdings Inc., short-term (operating) activity ratios
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
| Short-term activity ratio | Description | The company |
|---|---|---|
| Receivables turnover | An activity ratio equal to revenue divided by receivables. | IQVIA Holdings Inc. receivables turnover ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022 not reaching 2020 level. |
| Payables turnover | An activity ratio calculated as cost of goods sold divided by payables. | IQVIA Holdings Inc. payables turnover ratio increased from 2020 to 2021 but then slightly decreased from 2021 to 2022. |
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. | IQVIA Holdings Inc. number of days of receivables outstanding improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022 not reaching 2020 level. |
| Average payables payment period | An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. |
Receivables Turnover
IQVIA Holdings Inc., receivables turnover calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenues | 14,410) | 13,874) | 11,359) | 11,088) | 10,412) | |
| Trade accounts receivable and unbilled services, net | 2,917) | 2,551) | 2,410) | 2,582) | 2,394) | |
| Short-term Activity Ratio | ||||||
| Receivables turnover1 | 4.94 | 5.44 | 4.71 | 4.29 | 4.35 | |
| Benchmarks | ||||||
| Receivables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 5.16 | 5.63 | 5.19 | 6.13 | — | |
| Amgen Inc. | 4.46 | 4.96 | 5.36 | 5.47 | — | |
| Bristol-Myers Squibb Co. | 5.48 | 5.65 | 5.72 | 3.89 | — | |
| Danaher Corp. | 6.40 | 6.36 | 5.51 | 5.61 | — | |
| Eli Lilly & Co. | 4.14 | 4.24 | 4.18 | 4.91 | — | |
| Gilead Sciences Inc. | 5.65 | 6.01 | 4.98 | 6.18 | — | |
| Johnson & Johnson | 5.88 | 6.14 | 6.08 | 5.67 | — | |
| Merck & Co. Inc. | 6.27 | 5.28 | 6.11 | 6.91 | — | |
| Pfizer Inc. | 9.16 | 7.08 | 5.28 | 5.93 | — | |
| Regeneron Pharmaceuticals Inc. | 2.28 | 2.66 | 2.07 | 2.94 | — | |
| Thermo Fisher Scientific Inc. | 5.53 | 4.92 | 5.61 | 5.87 | — | |
| Vertex Pharmaceuticals Inc. | 6.19 | 6.66 | 7.01 | 6.57 | — | |
| Receivables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 5.75 | 5.53 | 5.33 | — | — | |
| Receivables Turnover, Industry | ||||||
| Health Care | 9.24 | 9.08 | 9.09 | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Receivables turnover = Revenues ÷ Trade accounts receivable and unbilled services, net
= 14,410 ÷ 2,917 = 4.94
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Receivables turnover | An activity ratio equal to revenue divided by receivables. | IQVIA Holdings Inc. receivables turnover ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022 not reaching 2020 level. |
Payables Turnover
IQVIA Holdings Inc., payables turnover calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of revenues, exclusive of depreciation and amortization | 9,382) | 9,233) | 7,500) | 7,300) | 6,746) | |
| Accounts payable | 645) | 621) | 581) | 575) | 437) | |
| Short-term Activity Ratio | ||||||
| Payables turnover1 | 14.55 | 14.87 | 12.91 | 12.70 | 15.44 | |
| Benchmarks | ||||||
| Payables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 5.94 | 6.05 | 6.76 | 5.12 | — | |
| Amgen Inc. | 4.08 | 4.72 | 4.33 | 3.18 | — | |
| Bristol-Myers Squibb Co. | 3.33 | 3.37 | 4.34 | 3.30 | — | |
| Danaher Corp. | 5.45 | 4.48 | 4.79 | 5.23 | — | |
| Eli Lilly & Co. | 3.43 | 4.38 | 3.41 | 3.36 | — | |
| Gilead Sciences Inc. | 6.25 | 9.36 | 5.42 | 6.56 | — | |
| Johnson & Johnson | 2.66 | 2.70 | 2.99 | 3.23 | — | |
| Merck & Co. Inc. | 4.08 | 2.96 | 3.37 | 3.78 | — | |
| Pfizer Inc. | 5.04 | 5.53 | 2.02 | 2.42 | — | |
| Regeneron Pharmaceuticals Inc. | 2.65 | 4.32 | 2.36 | 1.87 | — | |
| Thermo Fisher Scientific Inc. | 7.67 | 6.83 | 7.45 | 7.40 | — | |
| Vertex Pharmaceuticals Inc. | 3.55 | 4.64 | 4.75 | 6.25 | — | |
| Payables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 4.28 | 4.23 | 3.86 | — | — | |
| Payables Turnover, Industry | ||||||
| Health Care | 7.48 | 7.62 | 7.51 | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Payables turnover = Cost of revenues, exclusive of depreciation and amortization ÷ Accounts payable
= 9,382 ÷ 645 = 14.55
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Payables turnover | An activity ratio calculated as cost of goods sold divided by payables. | IQVIA Holdings Inc. payables turnover ratio increased from 2020 to 2021 but then slightly decreased from 2021 to 2022. |
Working Capital Turnover
IQVIA Holdings Inc., working capital turnover calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | 4,981) | 4,763) | 5,090) | 4,126) | 3,874) | |
| Less: Current liabilities | 5,578) | 5,241) | 4,558) | 3,945) | 3,534) | |
| Working capital | (597) | (478) | 532) | 181) | 340) | |
| Revenues | 14,410) | 13,874) | 11,359) | 11,088) | 10,412) | |
| Short-term Activity Ratio | ||||||
| Working capital turnover1 | — | — | 21.35 | 61.26 | 30.62 | |
| Benchmarks | ||||||
| Working Capital Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | 0.98 | — | |
| Amgen Inc. | 3.82 | 3.37 | 2.55 | 3.96 | — | |
| Bristol-Myers Squibb Co. | 8.30 | 3.95 | 3.72 | 2.28 | — | |
| Danaher Corp. | 4.20 | 8.40 | 3.48 | 0.87 | — | |
| Eli Lilly & Co. | 31.84 | 8.33 | 4.93 | 11.54 | — | |
| Gilead Sciences Inc. | 8.42 | 8.54 | 5.30 | 1.08 | — | |
| Johnson & Johnson | — | 5.95 | 9.44 | 8.81 | — | |
| Merck & Co. Inc. | 5.16 | 7.62 | 109.83 | 8.90 | — | |
| Pfizer Inc. | 11.00 | 4.78 | 4.58 | — | — | |
| Regeneron Pharmaceuticals Inc. | 0.96 | 1.59 | 1.20 | 1.41 | — | |
| Thermo Fisher Scientific Inc. | 5.46 | 5.87 | 2.76 | 4.48 | — | |
| Vertex Pharmaceuticals Inc. | 0.85 | 1.02 | 0.99 | 1.19 | — | |
| Working Capital Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 7.24 | 5.86 | 5.33 | — | — | |
| Working Capital Turnover, Industry | ||||||
| Health Care | 19.08 | 14.04 | 14.18 | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Working capital turnover = Revenues ÷ Working capital
= 14,410 ÷ -597 = —
2 Click competitor name to see calculations.
Average Receivable Collection Period
IQVIA Holdings Inc., average receivable collection period calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Receivables turnover | 4.94 | 5.44 | 4.71 | 4.29 | 4.35 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average receivable collection period1 | 74 | 67 | 77 | 85 | 84 | |
| Benchmarks (no. days) | ||||||
| Average Receivable Collection Period, Competitors2 | ||||||
| AbbVie Inc. | 71 | 65 | 70 | 60 | — | |
| Amgen Inc. | 82 | 74 | 68 | 67 | — | |
| Bristol-Myers Squibb Co. | 67 | 65 | 64 | 94 | — | |
| Danaher Corp. | 57 | 57 | 66 | 65 | — | |
| Eli Lilly & Co. | 88 | 86 | 87 | 74 | — | |
| Gilead Sciences Inc. | 65 | 61 | 73 | 59 | — | |
| Johnson & Johnson | 62 | 59 | 60 | 64 | — | |
| Merck & Co. Inc. | 58 | 69 | 60 | 53 | — | |
| Pfizer Inc. | 40 | 52 | 69 | 62 | — | |
| Regeneron Pharmaceuticals Inc. | 160 | 137 | 177 | 124 | — | |
| Thermo Fisher Scientific Inc. | 66 | 74 | 65 | 62 | — | |
| Vertex Pharmaceuticals Inc. | 59 | 55 | 52 | 56 | — | |
| Average Receivable Collection Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 63 | 66 | 69 | — | — | |
| Average Receivable Collection Period, Industry | ||||||
| Health Care | 39 | 40 | 40 | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 4.94 = 74
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. | IQVIA Holdings Inc. number of days of receivables outstanding improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022 not reaching 2020 level. |
Average Payables Payment Period
IQVIA Holdings Inc., average payables payment period calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Payables turnover | 14.55 | 14.87 | 12.91 | 12.70 | 15.44 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average payables payment period1 | 25 | 25 | 28 | 29 | 24 | |
| Benchmarks (no. days) | ||||||
| Average Payables Payment Period, Competitors2 | ||||||
| AbbVie Inc. | 61 | 60 | 54 | 71 | — | |
| Amgen Inc. | 90 | 77 | 84 | 115 | — | |
| Bristol-Myers Squibb Co. | 109 | 108 | 84 | 110 | — | |
| Danaher Corp. | 67 | 82 | 76 | 70 | — | |
| Eli Lilly & Co. | 106 | 83 | 107 | 109 | — | |
| Gilead Sciences Inc. | 58 | 39 | 67 | 56 | — | |
| Johnson & Johnson | 137 | 135 | 122 | 113 | — | |
| Merck & Co. Inc. | 89 | 123 | 108 | 97 | — | |
| Pfizer Inc. | 72 | 66 | 181 | 151 | — | |
| Regeneron Pharmaceuticals Inc. | 138 | 84 | 155 | 195 | — | |
| Thermo Fisher Scientific Inc. | 48 | 53 | 49 | 49 | — | |
| Vertex Pharmaceuticals Inc. | 103 | 79 | 77 | 58 | — | |
| Average Payables Payment Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 85 | 86 | 95 | — | — | |
| Average Payables Payment Period, Industry | ||||||
| Health Care | 49 | 48 | 49 | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 14.55 = 25
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average payables payment period | An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. |